Funded Biotechnology Startups in Watertown
Watertown, Massachusetts has produced a concentrated stream of biotechnology funding across the full spectrum of company stages, from Portal's $7M Seed rou…
Watertown, Massachusetts has produced a concentrated stream of biotechnology funding across the full spectrum of company stages, from Portal's $7M Seed round in December 2024 to Affini-T Therapeutics' $175M venture raise in March 2022. The 18 rounds in this view span early 2022 through June 2025 and include not only early-stage Series A activity but also Series B, Series E, and multiple Post-IPO tranches — reflecting a cluster that encompasses both emerging companies and publicly traded firms continuing to access capital markets.
Recent activity skews toward early and mid-stage deals: Corner Therapeutics closed a $54M Series A in April 2024, Syncell raised a $15M Series A in December 2024, and Parallel Bio secured a $21M Series A in June 2025. The largest disclosed amounts are concentrated in 2022–2023, anchored by Seismic Therapeutic's $121M Series B and Lyndra Therapeutics' $101M Series E, both closing in December 2023.
Most recent rounds
18 shownRelated listings
Frequently asked
What are the largest disclosed rounds among these Watertown biotech companies?
Affini-T Therapeutics leads at $175M (Venture - Series Unknown, March 2022), followed by Syros Pharmaceuticals at $130M (Post-IPO Equity, July 2022) and Seismic Therapeutic at $121M (Series B, December 2023). Neumora Therapeutics, Lyndra Therapeutics, and Lyra Therapeutics each cleared $100M or more in rounds between April 2022 and December 2023.
How active has Watertown biotech fundraising been in 2024 and 2025?
Six rounds closed in 2024, ranging from Dynamic Cell Therapies' $1M in July to Corner Therapeutics' $54M Series A in April. Two more followed in 2025: EnPlusOne Biosciences at $10M in February and Parallel Bio at $21M Series A in June.
What funding stages dominate the most recent rounds in this dataset?
The 2024–2025 cohort is weighted toward early and growth-stage: one Seed (Portal, $7M), three Series A rounds (Corner Therapeutics $54M, Syncell $15M, Parallel Bio $21M), and several Series Unknown tranches. Later-stage rounds — Series B, Series E, and Post-IPO — are concentrated in the 2022–2023 portion of the data.
Are there publicly traded companies in this group that continued raising after IPO?
Three Post-IPO rounds appear in the data, all closing within a five-month span in early 2022: Syros Pharmaceuticals raised $130M in Post-IPO Equity (July), Lyra Therapeutics raised $101M in Post-IPO Equity (April), and EyePoint Pharmaceuticals closed $45M in Post-IPO Debt (March).
How many rounds have ambiguous or undisclosed round types?
Four companies are classified as Series Unknown — EnPlusOne Biosciences, Dynamic Cell Therapies, Ingenia Therapeutics, and Selecta Biosciences — and Affini-T Therapeutics is listed as Venture - Series Unknown. Fluent BioSciences (March 2024) has neither a round type nor a disclosed amount.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.